- Home
- PRME vs DIAX Comparison
PRME vs DIAX Comparison
Compare PRME & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRME | DIAX |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | US | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 561.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | DIAX |
|---|---|---|
| Price | $3.34 | $15.67 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.42 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 94.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | ★ 24.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,983,000.00 | N/A |
| Revenue This Year | $95.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $12.42 |
| 52 Week High | $6.94 | $15.85 |
Technical Indicators
Market Signals| Indicator | PRME | DIAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 57.18 |
| Support Level | $3.16 | $15.56 |
| Resistance Level | $3.39 | $15.76 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 17.06 | 71.43 |
Price Performance
Historical ComparisonAbout PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.